Cutaneous drug reactions

Pharmacological Reviews

Volumn 53, Issue 3, 2001, Pages 357-379

  Svensson, Craig K ^a   Cowen, Edward W ^b   Gaspari, Anthony A ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPHOTERICIN B; AMPICILLIN; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CAPTOPRIL; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GOLD; HYDRALAZINE; LITHIUM; METRONIDAZOLE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PROTAMINE; QUINIDINE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

DISEASE PREDISPOSITION; DRUG ERUPTION; ERYTHEMA MULTIFORME; HUMAN; PHOTOALLERGY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; HUMANS; PHOTOSENSITIVITY DISORDERS; SKIN DISEASES;

EID: 0034843305     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (262)

1. Phenytoin-induced linear IgA bullous disease
2. Immune mechanisms of induction of penicillin allergy
3. Cutaneous drug reactions: Clinical types and causative agents
4. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
5. Incidence of rash and discontinuation of nevirapine using two different escalating doses
6. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program
7. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system
8. Penicillins and cephalosporins as allergens - Structural aspects of recognition and cross-reactions
9. Structure-activity studies of drug-induced anaphylactic reactions
10. Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects
11. Immunological physiopathology of cutaneous adverse drug reactions
12. Nevirapine and rashes
13. Rash with amoxycillinclavulanate therapy in HIV-infected patients
14. Drug hypersensitivity reactions and human immunodeficiency virus disease
15. Co-trimoxazole-induced liver injury - An analysis of cases with hypersensitivity-like reactions
16. Acute generalized exanthematous pustulosis
17. Drug-induced cutaneous reactions
18. Cutaneous reactions to non-steroidal anti-inflammatory drugs
19. Linear IgA deposition associated with cutaneous varicella-zoster infection: A case report
20. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia
21. An innate view of γδ T cells
22. γδ T cells in host defense and epithelial cell biology
23. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: A randomized multicentric study
24. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell immune mechanisms
25. Drug reactions
26. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
27. Cell-surface expression of heat shock proteins in dog neutrophils after oxidative stress
28. Role of desensitisation for drug hypersensitivity in patients with HIV infection
29. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients
30. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodytrophy, hyperlipidemia, and diabetes mellitus: A cohort study
31. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV
32. Studies of human IgE to a sulfonamide determinant
33. Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes
34. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus
35. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposure - Worldwide, 1997-2000
36. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions
37. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients
38. Mechanisms of drug allergy
39. Drug-protein conjugates XV. A study of the disposition of D-penicillamine in the rat and its relationship to immunogenicity
40. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes
41. Cutaneous disease and drug reactions in HIV infection
42. Cutaneous drug reactions in human immunodeficiency virus infection
43. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis
44. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity
45. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism
46. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
47. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins
48. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine
49. An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs
50. Sulfamethoxazole is metabolized to the hydroxylamine in humans
51. Recent advances in the pathology of cutaneous drug eruptions
52. Interleukin 1β and the stimulation of Langerhans cell migration: Comparisons with tumour necrosis factor α
53. Langerhans cells require signals from both tumour necrosis factor-α and interleukin-1β for migration
54. Inhibition by dexamethasone of Langerhans cell migration: Influence of epidermal cytokine signals
55. Modulation of epidermal Langerhans' cell frequency by tumour necrosis factor-α
56. Tumour necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization
57. Toxic epidermal necrolysis and trimethoprim
58. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients
59. Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction
60. Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients
61. Carbamazepine hypersensitivity syndrome: Report of 4 cases and review of the literature
62. Role of quaternary ammonium ion determinants in allergy to muscle relaxants
63. Sulfonamide hepatic injury
64. Phototoxicity and photoallergy
65. The clinical illness promotion factor: A third ingredient
66. National adverse drug reaction surveillance
67. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine
68. Adding lamotrigine to valproate: Incidence of rash and other adverse effects
69. New histopathologic findings in drug eruptions
70. A specific enzyme-linked immunosorbant assay for definition of the IgG antibody response to disulphide-conjugated D-penicillamine in the rabbit
71. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine
72. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils
73. The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro
74. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
75. Advances in understanding contact hypersensitivity
76. Allergy testing in serious cutaneous reactions - Harmful or beneficial?
77. Familial occurrence of hypersensitivity to phenytoin
78. Rapid oral desensitization to trimethoprimsulfamethoxazole (TMP-SMXZ): Use in prophylaxis for Pneumocystis carinii oneumonia in patients with AIDS who were previously intolerant to TMP-SMZ
79. Linear IgA disease of adults: Association with lymphoproliferative malignancy and possible role of other triggering factors
80. Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages
81. Adverse drug reactions (ADRs) in patients with HIV infection. A prospective study
82. Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires
83. Cefaclor serum sickness
84. Pseudoporphyria
85. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity
86. Keratinocyte intercellular adhesion molecule-1 (ICAM-1) expression precedes dermal T lymphocytic infiltration in allergic contact dermatitis (Rhus dermatitis)
87. Understanding drug allergies
88. Sulfonamide-induced reactions in desensitized patients with AIDS - The role of covalent protein haptenation by sulfamethoxazole
89. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine
90. Effect of nickel on the activation state of normal human keratinocytes through interleukin 1 and intercellular adhesion molecule 1 expression
91. Effect of various metals on intercellular adhesion molecule-1 expression and tumour necrosis factor alpha production by normal keratinocytes
92. Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy
93. Drugs as allergens: Detection and combining site specificities of IgE antibodies to sulfamethoxazole
94. Adverse virus-drug reactions
95. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes
96. High incidence of nevirapineassociated rash in HIV-infected Chinese
97. Allergy to antibiotics: T-cell recognition of amoxicillin is HLA-DR restricted and does not require antigen processing
98. Lamotrigine hypersensitivity in childhood epilepsy
99. Antibiotic rashes in children
100. The injured cell: The role of the dendritic cell system as a sentinel receptor pathway
101. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate
102. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions
103. N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus
104. Serum sickness-like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility
105. The skin immune system
106. Contact hypersensitivity: Immunological mechanisms
107. Langerhans cells and chemical allergy
108. Cytokine regulation of chemical sensitization
109. Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency
110. Hypersensitivity reactions to ampicillin in cytomegalovirus mononucleosis
111. Drug hypersensitivity syndromes
112. Photoreactions of 3,3′,4′-tetrachlorosalicylanilide with proteins
113. Carbamazepine-induced skin rash in children with epilepsy
114. Human autoantibodies against a desmosomal core protein in pemphigus foliaceus
115. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies
116. Angiotensin-converting enzyme inhibitor-induced pemphigus: Three case reports and literature review
117. Drug-induced linear IgA bullous dermatosis: Report of six cases and review of the literature
118. Enhanced computerized Bayesian assessment of suspected drug rashes with 'BARDI-Q&A'
119. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes
120. Improving the diagnosis of hypersensitivity reactions associated with sulfonamides
121. The role of dendritic cells in cutaneous immunity
122. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome
123. An intradermal test for the recognition of hypersensitivity to the sulfonamide drugs
124. Cutaneous manifestations of adverse drug reactions
125. Role of viral infections in the induction of adverse drug reactions
126. Anticonvulsant-induced toxic epidermal necrolysis: Monitoring the immunologic response
127. Fixed drug eruption: Bullous form
128. The participation of proliferative keratinocytes in the preimmune response to sensitizing agents
129. Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2
130. Prostaglandin synthase 2 expression in epidermal growth factor-dependent proliferation of mouse keratinocytes
131. Multifactor regulation of prostaglandin H synthase-2 in murine keratinocytes
132. Lymphocyte reactivity to ex vivo drug antigens in drug-induced hepatitis
133. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury
134. T cell recognition of haptens, a molecular view
135. Photoallergenicity of a fluoroquinolone antibacterial agent with a fluorene substituent at the 8-position in guinea pigs exposed to long-wavelength UV light
136. An innate sense of danger
137. Beyond 'self' and 'non-self': Immunity is a conversation not a war
138. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine
139. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
140. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins
141. Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds
142. Mechanisms of photosensitization by phototoxic drugs
143. A comparative study of photochemical sensitization by the non-steroidal anti-inflammatory drugs, naproxen, benoxaprofen and indomethacin
144. Photochemical studies on the anti-inflammatory drug diclofenac
145. Frequency and cost of serious adverse drug reactions in a department of general medicine
146. Regulation of cytochrome P450 during inflammation and infection
147. Regulation of cytochrome P450 by inflammatory mediators: Why and how?
148. Photobinding of carprofen to protein
149. Photobinding of ketoprofen in vitro and ex vivo
150. In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity
151. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions
152. Ampicillin sensitivity in infectious mononucleosis - Temporary or permanent?
153. Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction
154. Immunological functions of non-professional antigen-presenting cells: New insights from studies of T-cell interactions with keratinocytes
155. Direct and indirect control of T-cell activation by keratinocytes
156. Heat shock proteins and skin diseases
157. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis
158. Toxic epidermal necrolysis occurring during treatment with trimethoprim alone
159. Formation of antigenic quinolone photoadducts on Langerhans cells initiates photoallergy to systemically administered quinolone in mice
160. Fate of pemphigus antibody following successful therapy: Preliminary evaluation of pemphigus antibody determinations to regulate therapy
161. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype
162. Fatal toxic epidermal necrolysis related to lamotrigine administration
163. Erythema multiforme and toxic epidermal necrolysis: A comparative study
164. Trimethoprim-sulfamethoxazole desensitization in AIDS
165. Skin rash with infectious mononucleosis and ampicillin
166. Allergic rash due to antiepileptic drugs: Clinical features and management
167. Adverse reactions to dapsone in persons infected with human immunodeficiency virus
168. Paraphenylenediamine, a contact allergen, induces oxidative stress and ICAM-1 expression in human keratinocytes
169. Role of T cells in drug allergies
170. The link between sunshine and phototoxicity of sparfloxacin
171. Carbamazepine-hypersensitivity: Assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine
172. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro
173. Efavirenz associated with corticosteroid in patients with previous severe hypersensitivity reaction to nevirapine
174. Drug allergy
175. Carbamazepineinduced drug rashes: Diagnostic value of patch tests depends on clinicopathological presentation
176. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis
177. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity
178. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions
179. Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in HIV-infected individuals?
180. Time-course of toxicity of reactive sulfonamide metabolites
181. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
182. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites
183. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides
184. Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity
185. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro
186. Cutaneous reactions to drugs used for rheumatologic disorders
187. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia
188. Clinical aspects of skin reactions to NSAIDs
189. Toxic epidermal necrolysis (Lyell syndrome)
190. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
191. Severe adverse cutaneous reactions to drugs
192. Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes
193. Role of γδ T lymphocytes in immune response in humans and mice
194. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS
195. Intravenous trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonia
196. Lamotrigine-induced severe cutaneous adverse reactions
197. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus
198. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazoleinduced skin reaction
199. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones
200. Clinical drug photosensitivity: A retrospective analysis of reports of the Norwegian adverse drug reactions committee from the years 1970-1994
201. Successful prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
202. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk
203. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
204. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: Examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrazoline
205. Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice
206. Involvement of reactive oxygen species, protein kinase C, and tyrosine kinase in prostaglandin E2 production in Balb/c 3T3 mouse fibroblast cells by quinolone phototoxicity
207. The treatment of chorea with phenylethylhydantoin
208. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokinemediated apoptosis in demyelinating disease
209. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients with human immunodeficiency virus
210. Phenytoin hepatotoxicity: A review of the literature
211. Multifocal fixed drug eruption mimicking erythema multiforme
212. Predisposition to phenytoin hepatotoxicity assessed in vitro
213. Anticonvulsant toxicity in vitro: Possible role of arene oxides
214. Prevalence of cutaneous disorders in a population of HIV-infected patients
215. Cutaneous reactions to drugs
216. Dermatologic adverse drug reactions in hospitalized patients
217. Keratinocytes and immunological cytokines
218. Mechanisms of contact photosensitivity in mice. I. T cell regulation of contact photosensitivity to tetrachlorosalicylanilide under the genetic restrictions of major histocompatiblity complex
219. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study
220. Acute linear IgA dermatosis in a child following varicella
221. Heat shock proteins refine the danger theory
222. Quinolone photoallergy: Photosensitivity dermatitis induced by systemic administration of photohaptenic drugs
223. Photohaptenic properties of fluoroquinolones
224. Genetic control of contact photosensitivity to tetrachlorosalicylanilide. II. Igh complex controls the sensitivity induced by photohapten-modified spleen cells but not epidermal cells
225. Lymphocyte stimulation test with drug-photomodified cells in patients with quinolone photosensitivity
226. Allergy to carbamazepine: Parallel in vivo and in vitro detection
227. New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system
228. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions
229. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system
230. Skin reactions to antibacterial agents in general practice
231. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole
232. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
233. Antimicrobial photosensitive reactions
234. Anticonvulsant hypersensitivity syndrome
235. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human αβ+ T cell clones
236. Allergens and irritants transcriptionally upregulate CD80 gene expression in human keratinocytes
237. Nevirapine-associated Stevens-Johnson syndrome
238. Lymphocyte transformation studies in suspected hypersensitivity to trimethoprim-sulphamethoxazole
239. Cutaneous hypersensitivity reactions to thiacetazone. HIV infection and thiacetazone concentrations in plasma
240. Drug allergy
241. T cell responses to haptens. Structural models for allergic and autoimmune reactions
242. Nevirapineinduced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis
243. Desensitization to trimethoprim sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia
244. Trimethoprim-sulfamethoxazole therapy for the treatment of Pneumocystis carinii pneumonia
245. Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults
246. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
247. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants
248. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin
249. T cells ignore aniline, a prohapten, but respond to its reactive metabolites generated by phagocytes: Possible implications for the pathogenesis of toxic oil syndrome
250. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S
251. Sodium valproate acutely inhibits lamotrigine metabolism
252. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug induced hypersensitivity
253. Characterization of lidocaine-specific T cells
254. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αβ T lymphocytes
255. T cell reactions in patients showing adverse immune reactions to drugs
256. Photosensitizing activity of the anti-bacterial drugs sulfamethoxazole and trimethoprim
257. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children
258. The 97-Kda linear IgA bullous disease antigen is identical to a portion of the extra-cellular domain of the 180-Kda bullous pemphigoid antigen, BPAg2